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1. Introduction 
1.1 Inflammation 
Inflammation is a response of the organism that facilitates the immune response and/or 
repair after a harmful stimulus, such as pathogens, damaged cells, or irritants. The 
inflammatory process is necessary for the healing of the tissues. However, the uncontrolled 
chronic inflammation can also lead to harmful diseases, such as atherosclerosis or 
rheumatoid arthritis, among others (Eming et al., 2007; Tabas, 2010; Libby, 2008). 
The cause of inflammation may be of different origin. An inflammatory response could be 
stimulated by chemical or physical damages, but also by pathogens or immune reactions 
(Moore et al., 2010). 
The cardinal signs of inflammation in the majority of the tissues include pain, redness, 
immobility, swelling and heat. These signs usually encompass the increase of blood flow in 
the inflamed area and the accumulation of fluids that help to increase the possibilities of 
tissue repair. However, inflammation of particular tissues, such as in the central nervous 
system (CNS), those characteristics are not fully applicable (Carson et al., 2006). 
Many cells are implicated in the inflammatory process. One of the initial players is the 
resident macrophages, that are able to respond rapidly to damage. Particularly in the CNS, 
the macrophage-analogue cells are the resident microglia but their role is not fully 
understood and it is some how different from macrophages (Schwartz, 2003). Other tissue 
resident cells, like Dendritic cells or Kupfer cells, not present in the CNS, may also be initial 
responders to inflammation but other cells, entering in the CNS and coming from the 
systemic circulation, such as natural killer (NK) cells, leukocytes, and lymphocytes are also 
implicated in the inflammatory response (McMahon et al., 2006; Haskill et al., 1992). 
Inflammation also comprises a complex biological response implicating vascular tissues and 
the activation of the endothelium to facilitate the specific entrance of blood cells (Trepels et 
al., 2006). 
After a specific insult, several cascades of factors are activated. The plasma derived 
inflammatory mediators such as the complement and the coagulation system, together with 
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the cell-derived inflammatory mediators (Pesce and Dosekun, 1983). In the latter case, 
resident inflammatory cells start to release different factors that trigger and amplify the local 
inflammatory response. Among these factors, the cytokines and chemokines are the crucial 
players in the inflammation cascade (Luster, 1998) and, as we describe in depth in following 
sections of this chapter, are important mediators of the Acute Phase Protein (APP) response. 
Pro-inflammatory cytokines are proteins able to induce specific inflammatory responses in 
the tissue. Each type of cytokine participates in a particular function and it is specifically 
stimulated in particular scenarios and pathologies (Kopf et al., 2010). In the CNS, the 
cytokines play very important roles and their deregulation may result in neurological 
disorders. In fact, cytokines has been many times proposed as biomarkers for 
neurodegenerative diseases (Reale et al., 2009). The most studied cytokines, with clear 
effects in the CNS are the tumor necrosis factor alpha (TNF-), the interferon gamma (IFN-
), interleukin (IL)-6, IL-1 IL-17, and transforming growth factor beta (TGF-) among many 
others. 
TNF- is a cytokine involved in many inflammatory processes, with fundamental roles in 
inflammation and lymphoid organogenesis as well as in neuro-degenerative diseases (Idriss 
and Naismith, 2000). It is expressed by several cell-types including macrophages, 
lymphocytes and NK cells. Its deficiency or exacerbation may cause inflammatory and 
autoimmune diseases. The blockade of TNF- with specific antibodies has been largely 
developed with therapeutic purposes as for example anti tumor activity, but also it has been 
developed for brain disorders. 
IFN- is produced mainly in lymphocytes and NK cells and its expression by macrophages 
is still controversial. It has a crucial role in maintaining the host defense against pathogens 
and has been linked with the progression of many autoimmune diseases including those in 
the brain. Surprisingly, mice lacking IFN- or IFN- receptor (IFN-R) develop an 
exacerbated inflammation in models autoimmune diseases, which suggest that Th1 T cells, 
that produce IFN-, may be indirectly involved in these diseases (Jacob, 1992; Olsson, 1992). 
IL-1 is produced by several types of cells and it is involved in many inflammatory responses 
(Dinarello, 2006). The overproduction of IL-1 has been associated with a group of 
inflammatory disorders. Mice lacking the receptor for IL-1 or lacking both IL-1 and IL-1 
are protected from the development of autoimmune alterations. IL-1 promotes dendritic 
cell maturation and Th-17 cell clonal expansion, contributing to autoimmunity in brain 
diseases. The blockade of IL-1 has also been developed as a possible anti-cancer treatment 
(Dinarello, 2010; Curti et al., 1995) and may be beneficial to treat some brain degenerative 
disorders. 
IL-6 is produced by various cell types in response to infection or tissue alteration. 
Importantly, it is a crucial mediator of the immune system inducing a liver APP response 
and the B cell and T cell effector responses to pathogens (Hirano, 1992). Its target has 
therapeutic potential, since it is directly involved in some inflammatory diseases such as 
arthritis or colitis (Dayer and Choy, 2009; Atreya et al, 2000). As we describe below IL-6 is 
critically involved in the APP regulation. 
Chemokines also contribute to the specific inflammatory responses in the tissue. There are 
many types of chemokines involved in particular scenarios and pathologies similarly to 
cytokines. Importantly, chemokines play crucial roles in recruiting factors and cells into the 
parenchyma, contributing to enhance the local inflammatory response (Semple et al., 2010). 
Chemokines also may be considered biomarkers for tissue alteration. One of the most 
www.intechopen.com
Acute Phase Protein’s Levels as Potential  
Biomarkers for Early Diagnosis of Neurodegenerative Diseases 
 
91 
important subfamily of chemokines is the subgroup so called CC chemokine ligand (CCL). 
Examples of CC chemokine include the CCL2, formerly called monocyte chemoattractant 
protein-1 (MCP-1), which is involved in the extravasation and recruitment of macrophages 
and lymphocytes into the tissue. CCL5 or RANTES also contributes to the entrance of T 
cells, basophils and eosinophils (Ge et al., 2008). In the CNS, CCL2 seems to play a key role 
in some neurodegenerative diseases. Accordingly, in other neuro-inflammatory processes, 
such as acute brain trauma, stroke, as well as during chronic affections like multiple 
sclerosis or Alzheimer´s Disease (AD), prolonged and sustained inflammation mediated by 
CCL2 may have cytotoxic effects, aggravating the incidence and the severity of the disease 
(Conductier et al, 2010). Therefore, the CCL2 modulation may be considered as an 
interesting potential therapeutic target to control local inflammatory responses. 
This complex inflammatory response, driven by cytokines and chemokines, and 
consequently by APP, although it is necessary for the repair of the tissue, if is not controlled 
may contribute to the development of pathological conditions. Particularly in the CNS, 
increasing evidences show that the inflammatory response may be a crucial contributor to 
the neurodegenerative process. 
1.2 Inflammation and neurodegenerative diseases 
The inflammatory response in the CNS is very different from the rest of the systems. The 
particular anatomical location, inside the cranium, and the crucial importance of the brain 
function has shaped the need for a particular immune response. These characteristics have 
lead many scientists to think that the brain is an immune privileged tissue. The special brain 
blood barrier (BBB) and the absence of dendritic cells, or clear analogous cells, makes 
difficult to understand the mechanisms of the immune responses in the brain keeping in 
mind the standards of other tissues (Yong and Rivest, 2009). Glial cells, and in particular 
microglial cells, has been widely known as the initial responders of the immune response in 
the brain, however, there are many questions that remain unanswered regarding their 
function in neurodegenerative diseases (Henkel et al, 2009). 
The glial activation is a histological hallmark in many neurodegenerative diseases. Post 
mortem histopathology of brains from patients with Parkinson’s disease (PD) and AD show 
activation of microglial cells and astrocytes, which suggests that the neuronal degeneration 
is associated with inflammatory response (McGeer et al., 1988). However, it is still unclear 
whether glial activation precedes or is secondary to the neuro-degeneration. Previous 
studies in experimental Parkinsonism have shown that exacerbated microglial activation 
lead to the degeneration of dopaminergic neurons (Mount et al., 2007, Barcia et al., 2004). In 
line with this, when the microglial cells are activated locally with lipopolysaccharide (LPS), 
a large molecule found in the outer membrane of Gram-negative bacteria that elicits a strong 
immune response in animals, the local dopaminergic neuronal loss is exacerbated (Saijo et 
al., 2009). However, the endogenous and constitutive factors responsible of the local glial 
activation that may lead to degeneration in neurodegenerative disorders are still uncertain. 
Cytokines and chemokines are clear candidates to be directly involved in the activation of 
glial cells in the brain. Recent studies performed in our laboratory have shown in 
experimental models of PD that cytokines, specifically IFN- and TNF-, are responsible of 
the local glial activation in the brain parenchyma. Importantly, the levels of cytokines in the 
brain correlates with the neuronal degeneration and are persistently increased along the 
years, which suggest that the perpetuation of the neuronal loss may be mediated by certain 
cytokines (Barcia et al., 2011). Moreover, and most importantly for this review, the cytokines 
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are also increased in the circulating plasma demonstrating that the inflammatory response 
goes beyond the brain parenchyma in neurodegenerative processes. In addition, other 
studies have demonstrated that the artificial induction of increasing circulating levels of 
specific cytokines in the blood exacerbates the neuronal death in experimental models of 
neuro-degeneration in vivo (Pott Godoy et al., 2008). Coherently with this evidences, patients 
with neurodegenerative disorders also show increased levels of cytokines in the blood and 
cerebrospinal fluid (CSF), which suggests a general and systemic inflammatory response 
involving the whole organism (Reale et al., 2009). This generalized inflammatory response 
could certainly activate many other inflammatory cascades in other organs. One of the 
general responses that may be activated is the APP reaction. However, there are many 
proteins that are included in the APPs, and each disorder may have a particular response 
involving different proteins. Unfortunately, one of the caveats to keep in mind for this kind 
of measurements is the putative variation of these proteins that individuals may have when 
they are under pharmacological treatment. Nevertheless, the clinical significance of specific 
APP levels in serum or plasma of patients for specific neurological symptoms may be crucial 
in order to find biomarkers that may help for the early and accurate diagnosis of 
neurodegenerative diseases.  
1.3 Acute phase response and acute phase proteins  
The first reaction of the body to immunological stress is the innate, non-specific response 
preceding specific immune reactions. The acute phase response (APR) is a prominent 
systemic reaction of the organism as a result of this innate response to local or systemic 
disturbances in its homeostasis and may be caused by infection, tissue injury, trauma or 
surgery, neoplastic growth or immunological disorders (Gordon and Koy, 1985; Gruys et al., 
1999). 
This response takes place at the very beginning of the inflammatory process and lasts for 1-2 
days. After that, the host returns to normal functions. However, the systemic response can 
also be prolonged, if acute inflammation becomes chronic (Kushner et al., 1981). 
The purpose of acute-phase reaction is to counteract the underlying challenge in order to 
restore rapidly the homeostasis. This phenomenon is accomplished by isolating and 
destroying the infective organisms, or removing the harmful molecules, and activating the 
process of repair. Their function in neurodegenerative disorders is unclear but there are 
evidences that suggest their involvement and may be important for diagnosis. Acute-phase 
reaction includes a wide range of neuroendocrine (Fever, anorexia, decrease of thyroxine, 
increase of cortisol), hematopoietic (Anemia, leukocytosis, thrombocytosis), and metabolic 
changes (muscle atrophy, increase of lipolysis) that can be reflected systemically (Woo and 
Gorman, 1992; Whicher and Westacott, 1992).  
Precisely, one of the most interesting features of the acute-phase is the change in the 
concentrations of many plasma proteins, known as the acute-phase proteins, which can be 
easily detected in the blood. The APP has been defined as one whose plasma concentration 
increases (positive acute-phase proteins) or decreases (negative acute-phase proteins) by at 
least 25 percent during inflammatory reactions (Gabay and Kushner, 1999). The very first 
APP to be described, C-reactive protein (CRP), was discovered in 1930 in the plasma of 
patients during the acute phase of pneumococcal infection. In some pathologies CRP may 
even increase more than 1000 times (Gabay and Kushner, 2001) being an excellent marker 
for diagnosis. 
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1.4 The regulation of the acute-phase expression and activation 
The synthesis and release of plasma APP takes place in the liver and it is regulated by 
inflammatory mediators. These mediators fall into four major categories: IL-6-type 
cytokines, IL-1-type cytokines, glucocorticoids, and growth factors. Cytokines mainly 
stimulate the APP gene-expression, while glucocorticoids and growth factors modulate the 
cytokine activity (Figure 1). Binding of the inflammatory mediators to their respective 
receptors on hepatocytes and the transduction of this signal induce changes in APP gene 
expression that are primarily regulated at transcriptional level (Gauldie et al., 1987). 
As we stated above, cytokines are a group of proteins acting as extracellular and 
intercellular signaling molecules. The role of cytokines during inflammation is both 
initiation and fine-tuning of the whole process: some cytokines initiate and amplify the 
response, others sustain or attenuate it, and some of them cause it to resolve (Martínez-
Subiela, 2001, Heinrich et al., 1990). 
 
 
Fig. 1. Local inflammation in neurodegenerative diseases induces a Serum amyloid A  (SAA) 
APP peripheral inflammatory responses in a cytokine-dependent fashion. This APP 
response is orchestrated in the liver, and it is characterized by the increase of some factors 
such as CRP, fibrinogen or SAA and the reduction of some others like albumin. 
Furthermore, this response may contribute to the general inflammatory response and may 
exacerbate the local neuro-degeneration. 
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During inflammation, inflammatory cells, mainly macrophages and neutrophils that 
assemble at the site of challenge, together with endothelial cells, secrete the so-called pro-
inflammatory cytokines TNF-, IL-1, and IL-6, in that order. This order is important, 
since each cytokine fulfills a precise role in up-regulating or down-regulating the 
expression of the others. TNF-released by T cells and macrophages precedes the release 
of IL-1 and both stimulate the anti-inflammatory or proinflammatory cytokines 
(Feldmann, 2002). 
Pro-inflammatory cytokines induce a number of local and systemic responses like: a) the 
expression of selectins on local endothelial cells, that recruit inflammatory cells from the 
bloodstream; b) the activation of recruited cells in developing their optimal defensive 
activity, i.e. increased expression of receptors (Complement receptors), or cell metabolism, 
such as oxidative burst, and c) expression of other cytokines, such as chemokines, that 
recruit more and more defensive cells to the inflammation site (Richards et al.; 1992) and 
importantly d) the production of APPs. 
Then, cytokines are clear inducers of the APP response and both, cytokines and APP, may 
vary by the same pattern. However, changes in cytokines are less evident and more difficult 
to be measured while APPs changes are usually higher and clearly identifiable, which 
makes them suitable for early diagnosis. 
1.5 Classification of APP 
Since their discovery several classifications of acute phase proteins have been proposed. 
All the up-regulated proteins have been called “positive APP”, in order to differentiate 
them from the so-called “negative APP”, that are down regulated. Importantly, the most 
physiologically expressed proteins, albumin and several other proteins, usually present 
in blood, belong to the latter group, which makes the positive ones suitable for 
diagnosis. 
Another interesting classification differentiates the APPs for the rate of their expression. 
For example, the apolipoproteins serum amyloid SAA1 and SAA2 (commonly called 
SAA) are considered “major acute-phase proteins” and their concentration, as we have 
stated above, can increase as much as 1000-fold. Other major APPs are CRP and Alpha-1-
acid glycoprotein (AGP) (Gabay and Kushner, 2001) which are important for degenerative 
disorders. 
Relevant APPs for CNS disorders 
C-Reactive Protein (CRP) 
CRP is an acute phase protein that circulates as a pentamer (pentameric CRP) in plasma and 
with serum levels rising as much as 1000-fold following injury or infection. It is increased by 
bacterial infections and generally less elevated in viral infections (Jaye and  Waites, 1997). 
The name derives from its ability to react with the C polysaccharide of Streptococcus 
pneumoniae, but it may also bind to chromatin in nuclear DNA-histone complexes. Once 
bound, it is able to activate the classical complement pathway (Woo and  Gorman, 1992). 
An increased CRP may be due to: (i) inflammatory disorders, e.g. inflammatory arthritis, 
vasculitis, Crohn's disease, (ii) tissue injury or necrosis, e.g. burns, necrosis, myocardial 
infarction, pulmonary embolus, (iii) Infections, especially bacterial, (iv) malignancy, and (v) 
tissue rejection. 
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CRP concentrations typically return to normal level after 7 days of appropriated treatment 
for bacterial meningitis, if no complications are developed. Thus, serial monitoring of CRP 
concentrations in serum and CSF concentrations may be clinically useful. 
However, CRP is non-specific and its clinical usefulness is therefore limited, especially in 
diagnosis. CRP is useful in monitoring inflammatory disease activity, including rheumatoid 
arthritis, infections or malignancy and can also be useful as a prognostic marker for some 
conditions (e.g. acute pancreatitis). There is also evidence that CRP has a stronger predictive 
value for the risk of coronary heart disease and stroke events than low-density lipoprotein 
(LDL) cholesterol (Ridker et al., 2002), in contrast its predictive value for neurodegenerative 
diseases is still under development. 
Homocysteine 
Homocysteine (Hcy) is an amino acid formed from the metabolism of the essential amino 
acid, methionine. It is a homologue of the amino acid cysteine, differing by an additional 
methylene (-CH2-) group. It is biosynthesized from methionine by the removal of its 
terminal C methyl group. Homocysteine can be recycled into methionine or converted into 
cysteine with the aid of B-vitamins (Selhub, 1999). 
High dietary consumption of methionine, which can be found in meats and dairy products, 
can result in the overproduction of homocysteine. Once homocysteine is produced it is 
metabolized in the body through one of two possible pathways - remethylation or trans-
sulfuration. Re-methylation is a process that utilizes folate, vitamin B12 or betaine 
(trimethylglycine) to convert homocysteine back to methionine. Alternately, trans-
sulfuration utilizes vitamin B6, pyridoxal-5-phosphate, to catabolize excess homocysteine 
into a number of metabolites for eventual excretion from the body (Graham et al., 1997) and 
it can be increased in some neurodegenerative diseases, as we will describe below. 
Plasma homocysteine concentrations may differ, depending on which metabolic 
homocysteine pathway is defective. An abundance of research indicates that an increased 
homocysteine level may indicate an increased risk of cardiovascular disease like coronary 
heart disease, stroke and peripheral vascular disease (Boushey et al., 1995) 
Fibrinogen 
Fibrinogen is a soluble plasma glycoprotein, with high molecular weight of 340 kDa, 
synthesised by the liver that is converted by thrombin into fibrin during blood coagulation. 
This is achieved through a process in the coagulation cascade that activates the zymogen 
prothrombin to the serine protease thrombin, which is responsible for converting fibrinogen 
into fibrin. Fibrin is then cross-linked by factor XIII to form a clot (Weisel, 2005). 
Fibrinogen normal plasma levels are between 150 and 450 mg/dl. More than 300 mg/dl are 
related with the risk of heart attack. It is still controversial the role of fibrinogen as an 
atherosclerotic vascular disease risk factor; epidemiological evidences seem to be coincident 
about its role as a marker or predictor of new or reiterated atherothrombotic events 
(Paterno, 2000). 
The reasons by which fibrinogen is elevated in cardiovascular disease and atherosclerosis 
are, in general, only incompletely understood; but all cells involved in the atherogenetic 
process are able to produce cytokines, which induce an acute phase reaction that increases 
fibrinogen levels in plasma (Canseco-Ávila et al., 2006). 
Recent research has also shown that fibrin also plays a key role in the inflammatory 
response and the development of rheumatoid arthritis. In addition, it has been related with 
AD as we will discuss in following sections. 
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Serum amyloid A proteins (SAA) 
SAA constitutes a protein family related to the A proteins of secondary amyloidosis 
(Bausserman et al, 1980, 1982; Betts et al, 1991; Strachan et al, 1989).  
SAA is one of the major APPs (encoded by SAA1 and SAA2; collectively referred to also as 
A-SAA (acute phase serum amyloid A). Its level in the blood increases dramatically (up to 1 
000-fold; 1 000 micrograms/mL) in response to various stimuli, which suggests an 
important short-term beneficial role in responses to tissue injury and inflammation. 
Although the liver is the primary site of synthesis of both A-SAA and C-SAA, extrahepatic 
production has also been reported for most family members in most of the mammalian 
species studied. Bacterial lipopolysaccharides and several cytokines (mainly IL-1, IL-6 and 
TNF- but also LIF, CNTF, oncostatin M, IL-11, and cardiotrophin-1) are involved in the 
induction of SAA synthesis and some of these cytokines act synergistically (Benigni et al, 
1996).  
Although the precise role of A-SAA in host defense during inflammation has not been 
defined, many potential clinically important functions have been proposed for individual 
SAA family members. These include involvement in lipid metabolism/transport, induction 
of extracellular-matrix-degrading enzymes, and chemotactic recruitment of inflammatory 
cells to sites of inflammation. A-SAA is potentially involved in the pathogenesis of several 
chronic inflammatory diseases: it is the precursor of the amyloid A protein deposited in 
amyloid A amyloidosis, and it has also been implicated in the pathogenesis of 
atheroscelerosis, rheumatoid arthritis and, importantly, PD. 
2. Neurodegenerative diseases and Acute Phase Protein 
2.1 Alzheimer’s disease and APP 
AD is a complex neurodegenerative disorder characterized by progressive loss of cognitive 
function and subsequent death. Since the first case of this disease was diagnosed one 
century ago, much effort has been dedicated to find a cure. However, even though progress 
has been made in the knowledge of the pathogenesis of this disease, its ultimate cause 
remains unknown. An effective treatment has not yet been found and the efforts to prevent 
the neuronal death are crucial. Therefore, new approaches are urgently needed regarding 
the early diagnosis. 
The relevance of APP measurements in the diagnosis of neurodegenerative diseases like AD 
is actually under evaluation. Obviously, the inflammatory response generated in these kinds 
of illnesses is less noteworthy than the inflammatory response that may be observed in other 
pathological conditions such as viral or bacterial infections.  
A large number of proteins, peptides and aminoacids, other than β-amyloid, have been 
examined in plasma, based on their putative role in AD pathology. Perhaps the two most 
consistent findings are the increase in total Homocystein (tHcy) and CRP seen in AD. First 
reported by Clarke and colleagues, an increase of tHcy in plasma has been widely 
reported and a recent systematic review of large and prospective studies, found a relative 
risk of AD in individuals with elevated tHcy. Increased tHcy and CRP are both associated 
with a risk of cardiovascular disease but it is worth noting that neither contributes to risk 
estimation, even in cardiovascular disease, enough to warrant recommendation for use in 
clinical practice. Given that the association with AD may well be weaker than 
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cardiovascular disease, this emphasizes the gap between finding an association with 
disease and proof of utility as a biomarker. Nonetheless, CRP and tHcy may have 
independent effects on the risk of developing AD. Regarding CRP, the studies are some 
how controversial and complex. Some studies reported that an elevation in CRP has been 
associated the rate of progression of AD but also with MCI and Down’s syndrome. 
However, other large longitudinal studies found that markers of inflammation, such as 
TNF- but not CRP, were associated with the risk of dementia while others found an 
association between CRP and vascular dementia (VD). 
Accordingly, a recent study by O’Bryant and colleagues (2010) analyzing a combined pool of 
192 patients diagnosed with probable AD and 174 non-demented controls show that mean 
CRP levels were found to be significantly decreased in AD (2.9 mg/mL) versus controls (4.9 
mg/mL; P<.003). These findings, together with previously published results, are consistent 
with the hypothesis that these changes in CRP may be time-dependent, therefore, midlife 
elevations in CRP may be associated with increased risk of AD development, although 
elevated CRP levels may not be useful for prediction in the immediate prodrome years 
before AD becomes clinically expressed.  
There is significant evidence that AD patients suffer from inadequate circulation and 
cerebrovascular pathology, and one theory that is gaining evidence is the importance of 
vascular factors in the onset and progression of this disease (Farkas et al., 2001; Iadecola C, 
2004; de la Torre 2004). In line with this, AD patients have an abnormal cerebral vasculature 
and brain hypoperfusion, and a large body of research, implicates cerebrovascular 
dysfunction as a contributing factor to AD.  Some recent studies show how reducing 
fibrinogen, a circulating protein critical in hemostasis, provides a significant decrease in the 
neurovascular damage, blood–brain barrier permeability and neuroinflammation present in 
AD. These studies involve fibrinogen as a possible contributor to AD (Cortes-Canteli and 
Strickland, 2009). 
On the other hand, some other studies show increased levels of tHcy in patients with 
probable AD and established negative correlation between serum tHcy concentrations and 
cognitive damage tested By Mini-Mental State Examination (MMSE) scores, suggesting a 
potential role for tHcy in the pathogenesis of AD and cognitive impairment (Lepara et al., 
2009). 
These findings imply that the serum tHcy level may be a potential biomarker for AD, as well 
as a marker of cognitive damage associated with this disease. 
2.2 Parkinson’s disease and APP 
PD is a neurodegenerative disorder characterized by the loss of dopaminergic neurons of 
the Substantia Nigra pars compacta (SNpc). A big problem with this particular disease is that 
the neurological symptoms only appear when more than 60% of the neurons are already 
lost. For this reason the early diagnosis is crucial to prevent the neuronal degeneration. The 
areas of neurodegeneration are accompanied by local inflammation characterized by a 
strong glial response mediated by cytokines. These proinflammatory compounds also travel 
outside the brain and can be detected in the blood. 
It is known that some cytokines, such as IL1-, TNF- and IFN-, are increased in the 
blood and cerebrospinal fluid (CSF) of patients with PD. These cytokines are able to 
reactivate the local inflammation in the CNS but they are also able to induce the activation 
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of other peripheral inflammatory pathways such as the activation of APP. Then, the 
measurement of blood APP levels may be a valuable tool for assessing and confirming the 
early diagnosis in Parkinsonism, and the secretion of these anti-inflammatory markers 
such as cytokines or APPs could be utilized to help the diagnose of the disease (de Pablos 
et al., 2009). 
There are very few studies regarding the levels of APP in PD and some of the results are 
apparently in conflict. Dufek and coworkers (2009) only found sporadic and slight 
abnormalities in the concentration of CRP and SAA in the serum of PD patients but McGeer 
and coworkers (2004), however, observed an increase of CRP in the affected dopaminergic 
areas of the brain. This apparent contradiction may be explained since the patients studied 
by Dufek and colleagues were moderately impaired and were all taking antiparkinsonian 
drugs, which may interfere in the peripheral APP measurements. In fact, a study of our 
laboratory shows that tHyc is increased in PD patients under L-dopa treatment (Martín-
Fernández et al., 2010). On the other hand, other study regarding the APP levels in the blood 
of PD patients show an increase of CRP in the plasma according with the Hoehn-Yahr stages 
of PD severity (Seet et al., 2009). Importantly, in the study of Seet and coworkers the patients 
were advised to refrain from consuming their anti-parkinsonian medications 4 h before 
collection of the samples suggesting that a previous wash out of drugs may be needed in 
order to detect changes in these proteins. These results suggest that the dopaminergic loss in 
the brain is able to induce an increase of the peripheral APP that can be detected in the 
serum. In line with this, previous studies of our group have demonstrated that the specific 
degeneration of dopaminergic neurons induced by MPTP administration in non-human 
primate, stimulates an increase of CRP, SAA and Haptoglobin (HP) in plasma (de Pablos et 
al., 2009). This increase is very fast and transient, except for HP, which suggest that this 
response is related with the immediate effect of the toxin. On the other hand, a persistent 
increase of APP in the plasma suggests a persistent damage, which can be related with 
chronic degeneration. 
The role of APP in PD is still unclear but increasing evidences show that the local 
inflammatory response in the brain is also reflected by several markers systemically and 
may be easily detected in the blood by well-established techniques. CRP seems to be a clear 
candidate as a PD biomarker but further studies are needed to soundly determine the 
specific factors that are increased in PD, which APPs are particularly increased and how are 
they correlated with the dopaminergic degeneration and the level of Parkinsonism.  
2.3 Vascular dementia and APP 
Several inflammatory proteins, such as cytokines are linked with AD and some APP, such as 
tHcy and CRP, has been associated with the disease (Clarke et al., 1998). However, the 
relation between the APP and the presence of absence of dementia is still unclear. Very few 
studies report changes in the APP levels in VD and some of them present inconclusive 
results. Mancinella and coworkers (Mancinella et al., 2009) described that CRP levels are 
elevated in patients with VD respect to controls but still they show lower levels than 
patients with AD, which makes difficult to distinguish both disorders based in the 
peripheral biomarkers. Other authors did not find any differences in the CRP levels in VD 
but they however found an increase in tHcy (Davis et al., 2009). Importantly, high blood 
levels of tHcy have been related with cardiovascular diseases and may be also related with 
similar alterations in the VD (Lepara et al., 2009). 
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A. Proteins whose plasma concentrations increase
  Complement system
     C3
     C4
     C9
     Factor B
     C1 inhibitor
     C4b-binding protein
     Mannose-binding lectin
  Coagulation and fibrinolytic system
     Fibrinogen
     Plasminogen
     Tissue plasminogen activator
     Urokinase
     Protein S
    Vitronectin
    Plasminogen-activator inhibitor 1
  Antiproteases
-1 -Protease inhibitor 
 -Antichymotrypsin 
     Pancreatic secretory trypsin inhibitor
      Inter -trypsin inhibitors 
  Transport proteins
     Ceruloplasmin
     Haptoglobin
     Hemopexin
  Participants in inflammatory responses
     Secreted phospholipase A2
     Lipopolysaccharide-binding protein
     Interleukin-1–receptor antagonist
     Granulocyte colony-stimulating factor
  Others
     C-reactive protein
     Serum amyloid A
1 -Acid glycoprotein 
     Fibronectin
     Ferritin
     Angiotensinogen
B. Proteins whose plasma concentrations decrease
     Albumin
     Transferrin
     Transthyretin
Alpha-2-HS glycoprotein 
     Alpha-fetoprotein
     Thyroxine-binding globulin
     Insulin-like growth factor I
     Factor XII
Table 1. Human Acute-Phase proteins. 
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Fig. 2. Different inflammatory triggering factors activate cells to stimulate local reactions. 
This response is mediated by different cytokines that are able to provoke a secondary 
systemic reaction characterized by the increase of leukocytes, activation of complement, 
increase of glucocorticoids in serum, reduction of Fe++ and Zn+ and the cascade of APPs. 
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Acute Phase Protein 
Normal concentration in 
plasma (mg/l) 
GROUP 1 
(50% increase) 
Ceruloplasmin 150-600 
C3-Complement  800-1700 
C4-Complement 150-650 
GROUP 2 
(2-5-fold increase) 
Haptoglobin 400-1800 
1-glycoprotein 550-1400 
1 antichemotrypsin 300-1600 
1  protease inhibitor protease 2000-4000 
Fibrinogen 2000-4500 
GROUP 3 
(1000 -fold increase) 
C-Reactive Protein < 5.0 
Serum Amyloid A <10.0 
Table 2. APP Classification production depending on the rate of their expression and normal 
concentration in human. 
3. Conclusions and therapeutic perspectives 
In neurodegenerative diseases changes observed blood parameters could be considered as 
putative hallmark of diseases evolution that might be helpful for personalized diagnosis, 
prognostic and/or progression diseases monitoring.  
Obviously, the inflammatory response triggered in neurodegenerative diseases such as PD 
or AD is less easily detectable than those observed in other pathological conditions such as 
viral or bacterial infections. Accordingly, the APPs increase observed in neurodegenerative 
diseases is of less extent than the increase observed in infectious pathologies. Therefore, it is 
to be expected that the increase in APPs in patients exhibiting neurodegenerative diseases 
will be low as compared with other diseases. Although the relevance of APP measurements 
in the diagnosis of neurodegenerative diseases should need further evaluations, we believe 
that the prospects for blood-based biomarkers may be useful in the near future. We suggest 
that blood-based APP markers, perhaps in association with other biomarkers, will be useful 
tools for diagnosis of neurodegenerative diseases such as AD or PD and it is very likely that 
plasma markers will become part of the armamentarium for the investigation of CNS 
disorders. 
The measurement of blood APP levels will be a safe and valuable tool for assessing and 
confirming the diagnosis of some disorders; the secretion of anti-inflammatory markers such 
as cytokines or APPs could be used to help to diagnose and evaluate the progression of the 
neurodegenerative process. However, more sensitive techniques of APP detection are 
needed, in particular to be used as putative diagnosis marker of neurodegenerative 
disorders. 
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